Hennion & Walsh Asset Management, Inc. 89bio, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.1 Billion
- Q4 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in 89bio, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 94,494 shares of ETNB stock, worth $583,972. This represents 0.03% of its overall portfolio holdings.
Number of Shares
94,494Holding current value
$583,972% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding ETNB
# of Institutions
162Shares Held
108MCall Options Held
73.6KPut Options Held
1.19M-
Janus Henderson Group PLC London, X015.2MShares$93.7 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$87.6 Million1.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.99MShares$49.4 Million2.33% of portfolio
-
Rtw Investments, LP New York, NY7.38MShares$45.6 Million0.87% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$43.4 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $287M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...